← Back to Search

Monoclonal Antibodies

Erenumab for Migraine

Phase 4
Waitlist Available
Led By Todd J Schwedt
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 8 weeks
Awards & highlights

Study Summary

This study is evaluating whether a drug can change brain function and structure in people with migraines.

Eligible Conditions
  • Migraine

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~8 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 8 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Resting State Functional Connectivity
Secondary outcome measures
Change in the Migraine Disability Assessment Questionnaire (MIDAS)
Erenumab Responders
Iron Accumulation in Anterior Cingulate Cortex Brain Region
+7 more

Side effects data

From 2023 Phase 4 trial • 701 Patients • NCT04084314
35%
COVID-19
19%
Nasopharyngitis
15%
Constipation
9%
Fatigue
7%
Hypertension
6%
Back pain
6%
Immunisation reaction
6%
Headache
6%
Migraine
6%
Depression
5%
Nausea
5%
Arthralgia
4%
Vertigo
4%
Alopecia
4%
Pain in extremity
3%
Tonsillitis
3%
Cystitis
3%
Urinary tract infection
3%
Dizziness
3%
Oropharyngeal pain
3%
Pruritus
3%
Pyrexia
3%
Cough
3%
Chills
2%
Diarrhoea
2%
Post vaccination fever
2%
Abdominal pain upper
2%
Muscle spasms
2%
Osteoarthritis
2%
Procedural pain
1%
Appendicitis
1%
Intervertebral disc protrusion
100%
80%
60%
40%
20%
0%
Study treatment Arm
Erenumab

Trial Design

1Treatment groups
Experimental Treatment
Group I: ErenumabExperimental Treatment1 Intervention
All participants receive erenumab 140mg by subcutaneous injection at baseline and again 4 weeks later.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Erenumab
FDA approved

Find a Location

Who is running the clinical trial?

Mayo ClinicLead Sponsor
3,213 Previous Clinical Trials
3,766,961 Total Patients Enrolled
9 Trials studying Migraine
81,756 Patients Enrolled for Migraine
Todd J SchwedtPrincipal InvestigatorMayo Clinic

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Imaging the Migraine Brain Pre- and Post-Erenumab
Todd J. Schwedt 2019. "Imaging the Migraine Brain Pre- and Post-Erenumab". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03773562.
~8 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top